"Do I have hypodermic needles around me?" From a macro perspective, no matter where you are in the world, there is an extremely high chance that the needles you use are closely linked to Chinese manufacturing. They may bear well‑known international brand names such as BD or Terumo, or carry the label "Made in Weihai". Within the global medical device industrial chain, China has become the undisputed manufacturing hub for single‑use sterile syringes and needles, accounting for more than 70 % of global output. Amid this vast industrial landscape, the rise of Weihai Weigao International Medical Investment Holding Co., Ltd. (Weigao Group) is not merely a corporate success story, but a micro‑epic depicting Chinese manufacturing's transformation from cost‑driven advantages to quality‑ and innovation‑led growth.

From World Factory to Global Supplier: Industrial Upgrading of Chinese‑Made Needles

In the 1990s, leveraging low labour costs and a complete industrial supporting system, China entered the syringe and needle market - a sector with relatively low technical barriers yet enormous demand. Initially, Chinese manufacturers operated as OEM/ODM contractors. However, as market competition intensified and global regulatory requirements tightened (including the US FDA 510(k) pathway and the EU MDR), pure cost‑based competition became unsustainable. Leading Chinese enterprises represented by Weigao achieved crucial breakthroughs through continuous quality improvement and technological research, evolving from low‑end contract manufacturers to exporters of independent brands, and from imitators to innovators in select fields.

Weigao Group: Ambition for a Full Industrial Chain Behind a Single Needle Cannula

Founded in 1998, Weigao started with single‑use infusion sets and syringes. Its core strategic focus lies in building vertically integrated full‑industrial‑chain capabilities, which are fully demonstrated in its hypodermic needle business:

Independent raw‑material production: Weigao owns subsidiaries producing medical‑grade polymer and metallic materials, enabling in‑house manufacturing of high‑purity polypropylene and stainless‑steel wire for needle cannulas, controlling quality and cost from the source.

Breakthroughs in core manufacturing processes: Needle production hinges on stainless‑steel tube drawing, cutting and tip sharpening. Having invested heavily in importing and developing high‑precision automated needle‑making equipment, Weigao has reached internationally advanced levels in multi‑facet tip grinding and electropolishing of inner cannula surfaces, ensuring superior sharpness, rigidity and smoothness. Its insulin pen needles are available in ultra‑fine 34G specifications, challenging technical barriers set by global industry giants.

Comprehensive product portfolio: Weigao's single‑use injection needle lineup is highly diversified, covering standard injection needles, insulin pen needles, blood‑collection needles, safety injection needles, indwelling needles, and pre‑filled syringe components matched with syringes, fully meeting diverse market demands.

Quality systems and international certifications: Weigao has established internal control standards stricter than global norms. Its major production facilities are certified to ISO 13485, US FDA standards and EU CE requirements, allowing its products to be sold worldwide and directly enter high‑standard mainstream markets in Europe and North America.

Global Influence Driven by Dual Advantages of Cost and Quality

Weigao's competitiveness has evolved from pure cost advantages to value‑for‑money superiority: delivering quality comparable to top international brands while maintaining distinct cost‑effectiveness. This has profoundly reshaped the global supply‑chain landscape:

OEM production for international brands: Weigao serves as a core supplier for several of the world's top medical‑device firms, providing high‑quality cannulas and finished needles under OEM arrangements.

Overseas expansion of self‑owned brands: Under proprietary brands such as JieRui, its products are exported to numerous countries and regions across Asia, Africa, South America and Europe, supplying affordable high‑quality medical devices for local populations.

Securing domestic demand and public‑health safety: As China's largest supplier, Weigao has undertaken national strategic stockpiling and supply assurance tasks during major public‑health emergencies such as large‑scale COVID‑19 vaccination campaigns, embodying the pillar role of national enterprises.

A New Meaning of "Made in China" Around Us

Therefore, when you receive a vaccination at a community clinic or purchase a domestically manufactured syringe from a pharmacy in China, the needle you hold is most likely produced by Weigao. Similarly, medical devices manufactured in Weihai may be used in European clinics or African aid stations. These tiny needles no longer carry the label of "low‑cost goods", but represent the comprehensive strengths of Chinese manufacturing in precision quality, large‑scale production and supply‑chain resilience.

Weigao's story epitomises the transformation and upgrading of "Made in China" within the medical‑consumable sector. It proves that through sustained technological investment, deep integration of the full industrial chain and adherence to international quality standards, Chinese enterprises can grow into indispensable hidden champions in global supply chains and earn worldwide recognition through independent brands. This ordinary needle beside us is becoming a precise yet resilient "Chinese business card" connecting China to global healthcare initiatives.